Evolocumab

Evolocumab has been studied in 88 papers since 2017: 22 trials and 29 observational studies in people, 1 in animals, 28 reviews; 75 in the past year. It is an approved medicine. The newest story, Nov 11, 2026: “Evolocumab cut combined heart and stroke risk in kidney impairment”.

InterventionApproved 2015

88 papers study it94 findingsUpdated

MeSH

Part of Bryan Johnson's Blueprint

40 new papers in 30 daysSee all 86 papers on evolocumab

At a glance

Human trials report fewer cardiovascular events with evolocumab in high-risk patients without prior myocardial infarction or stroke; independent labs also report lower cardiovascular event risk and LDL cholesterol in humans. An open-label extension shows no clear effect on executive function. Some papers declare ties to its developer, Amgen.

94 findings in 45 papers from 2021 to 2026, 25 of them since May 2026

Independent labs found the same change in people. 29 independent labs in 17 countries; 93 trials, 11 about aging, 7 with no results posted.

“Evolocumab reduced the relative rate of any stroke by 24% compared with placebo (5-Yr Kaplan-Meier, 2.6% vs 3.2%; HR 0.76, 95% CI 0.61-0.95; p=0.018)”
Evolocumab for Stroke Prevention in Patients at High CV Risk Without a Prior Stroke or MI in VESALIUS-CVAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.17609

None of its findings points the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 29 independent labs in 17 countries
  • 93 trials, 11 about aging, 7 with no results posted
  • Funders: Amgen and others
  • 41 of 87 findings with company ties
  • 52 of 93 trials sponsored by its developers
  • Human trial22
  • Humans29
  • Animals1
  • In silico2

19 studies gave evolocumab to people and measured what changed.

What changedDesignPeopleSource

up: Increases skeletal muscle volume2165±535 to 2435±719 mL

down: Decreases epicardial adipose tissue volume118.1±42.4 to 104.7±40.8 mL

no change: Has no effect on body weight190±34 to 191±34 lb; p=0.66

Trial18 months35 peopleSingle-arm before-and-after comparison in patients with extensive noncalcified plaque burdenAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Lowers the risk of strokeHR 0.76, 95% CI 0.61-0.95

down: Decreases LDL cholesterol45 mg/dL vs 109 mg/dL

Randomized trial4.6 years2,014 peoplePatient cohortsAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases LDL cholesterol44 mg/dL versus 111 mg/dL

down: Lowers the risk of 3-P MACE39% reduction; HR 0.61, 95% CI 0.46–0.81; 5-year ARR 4.0%

down: Lowers the risk of mortality12.0% versus 16.7%; HR 0.71, 95% CI 0.56–0.90

Randomized trial48 weeks2,140 peopleBothMedian 69 years (IQR 64, 73)Older adults; Patients with CKD in the lipid substudyAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases LDL cholesterol44 mg/dL versus 111 mg/dL with placebo

down: Decreases 3-point major adverse cardiovascular events39% reduction; HR 0.61, 95% CI 0.46-0.81; 5-year absolute risk reduction 4.0%

down: Decreases mortality12.0% versus 16.7%; absolute risk reduction 4.7%; HR 0.71, 95% CI 0.56-0.90

Randomized trial48 weeks2,140 peopleBothMedian 69 years [64-73]Older adults; Reduced eGFR; lipid substudyJournal of the American College of Cardiology, Nov 1, 2026

down: Lowers the risk of first myocardial infarction36% risk reduction; HR 0.64, 95% CI 0.52–0.79; 5-year Kaplan-Meier incidence 2.7% vs 4.1%

Randomized trialMedian follow-up of 4.6 years12,257 peopleQualifying atherosclerosis or high-risk diabetes, no prior myocardial infarction or stroke, and LDL-C ≥90 mg/dLESC Congress 2026 abstract, Oct 26, 2026

What did studies of evolocumab find?

43

Studies of evolocumab measured 43 outcomes; the most studied are LDL cholesterol (14 studies), LDL-C (5) and mortality (4).

LDL cholesterol

downin humans14

14 studies
  1. Evolocumab decreases LDL cholesterol in humans (Added to ezetimibe in ataxia-telangiectasia with severe mixed atherogenic dyslipidemia) (149 to 35 mg/dL; triglycerides to 220 mg/dL; HbA1c to 5.9%).

    “After evolocumab was added to ezetimibe, low-density lipoprotein cholesterol decreased from 149 to 35 mg/dL”

    Human trialAdded to ezetimibe in ataxia-telangiectasia with severe mixed atherogenic dyslipidemiafemalesn = 1

    Severe Atherogenic Dyslipidemia in Ataxia-Telangiectasia Despite Cachexia: Mechanistic Insights into Mitochondrial Dysfunction

    The Yale journal of biology and medicine

  2. Evolocumab decreases LDL cholesterol in humans (Patients with CKD in the lipid substudy; compared with placebo) (44 mg/dL versus 111 mg/dL).

    “median LDL cholesterol level at 48 weeks was 44 mg/dL (IQR, 28-71) in the evolocumab group and 111 mg/dL (IQR, 83-146) in the placebo group”

    Human trialPatients with CKD in the lipid substudy; compared with placebo48 weeks

    Evolocumab reduced cardiovascular risk in kidney disease

    AHA Scientific Sessions 2026 abstract

  3. Evolocumab decreases LDL cholesterol in humans (45 mg/dL vs 109 mg/dL).

    “In a lipid substudy (N=2014), the median LDL cholesterol level at 48 weeks was 45 mg/dL (IQR, 26-73) in the evolocumab group and 109 mg/dL (IQR, 86-144) in the placebo group.”

    Human trial48 weeksn = 2,014

    Evolocumab reduced first-stroke risk in high-risk patients

    AHA Scientific Sessions 2026 abstract

  4. Evolocumab decreases LDL cholesterol in humans (Reduced eGFR; lipid substudy) (44 mg/dL versus 111 mg/dL with placebo).

    “the median LDL-C at 48 weeks was 111 mg/dL in the placebo group versus 44 mg/dL in the evolocumab group (p<0.0001).”

    Human trialReduced eGFR; lipid substudy48 weeks

    Evolocumab cut combined heart and stroke risk in kidney impairment

    Journal of the American College of Cardiology

  5. Evolocumab decreases LDL cholesterol in humans (-73.5% vs -48.3%).

    “The 12-month LDL-C percentage reduction was -73.5% with ELLT, and -48.3% with LLT (p=0.0001).”

    Human trialon top of lipid-lowering therapy in patients with carotid stenosis >=50% and LDL-C >=100 mg/dL12 monthsn = 170

    CARotid plaqUe StabilizatiOn and regression with evolocumab: the CARUSO Study

    medRxivPreprint

  6. Evolocumab decreases LDL cholesterol in humans (added to empagliflozin) (-61 ± 27%).

    “EE therapy reduced LDL cholesterol by 61 ± 27% (intragroup and intergroup p < 0.001)”

    Human trialadded to empagliflozin16 weeksn = 110

    LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial

    Atherosclerosis

  7. Evolocumab decreases LDL cholesterol in humans (12 weeks into open-label extension) (median 35 mg/dl (IQR 21-55 mg/dl)).

    “At 12 weeks into the open-label extension period, median LDL cholesterol across the overall population was 35 mg/dl”

    Human trial12 weeks into open-label extension12 weeks

    Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab

    NEJM evidence

  8. Evolocumab is linked with lower LDL cholesterol in humans (−58.9% (−2.09 mmol/L), unadjusted).

    “mean unadjusted LDL-C reductions were − 58.2% (–1.98 mmol/L), − 58.9% (–2.09 mmol/L), and − 33.2% (–1.17 mmol/L), respectively (p < 0.001).”

    Humansn = 693

    Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study

    Lipids in health and disease

  9. Evolocumab is linked with lower LDL cholesterol in humans (initiated in hospital on top of high-intensity statin therapy) (52 ± 11 vs 82 ± 18 mg/dL at 24 months).

    “at 24 months, mean LDL-C was 52 ± 11 mg/dL (EVOLOCUMAB) vs. 82 ± 18 mg/dL (STANDARD, p < 0.001)”

    Humansinitiated in hospital on top of high-intensity statin therapy140 mg every two weeks24 monthsn = 71

    Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting

    Frontiers in cardiovascular medicine

  10. Evolocumab decreases LDL cholesterol in humans.

    “The monoclonal antibodies evolocumab and alirocumab substantially reduce LDL-C levels and cardiovascular risk”

    Review

    PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

    International journal of molecular sciences

All 14

More on LDL cholesterol

LDL-C

downin humans5−69%

5 studies
  1. Evolocumab decreases LDL-C in addition to high-intensity statin therapy (between-group difference, −1.2 mmol/L [95% CI, −1.5 to −1.0]).

    “However, evolocumab-treated patients showed greater improvement in all lipid parameters in the 12-week treatment period, including LDL-C (between-group difference, −1.2 mmol/L [95% CI, −1.5 to −1.0], i.e., −47.7 mg/dL [95% CI, −56.9 to −38.6]; p < 0.001).”

    Human trialin addition to high-intensity statin therapy12 weeksn = 85

    Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial

    Clinical research in cardiology : official journal of the German Cardiac Society

  2. Evolocumab decreases LDL-C in statin-naïve ACS patients undergoing PCI (31±16 mg/dL vs. 63±17 mg/dL, -77.5% vs. -53.3%).

    “At 2 weeks, LDL-C levels were lower in the evolocumab group compared to the non-evolocumab group (31±16 mg/dL vs. 63±17 mg/dL; p<0.001)”

    Human trialin statin-naïve ACS patients undergoing PCI140 mg2 weeksn = 108

    Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

    Korean circulation journal

  3. Evolocumab is linked with lower LDL-C in humans (add-on to statin in CHIP-NSTEACS patients) (61.3% vs. 32.2%).

    “At 3 months, LDL-C reduction was 61.3% in the observation group vs. 32.2% in the control group (P < 0.001)”

    Humansadd-on to statin in CHIP-NSTEACS patients3 months

    Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study

    Frontiers in cardiovascular medicine

  4. Evolocumab is linked with lower LDL-C in multidisciplinary cardiometabolic clinic patients (-69%).

    “Median low-density lipoprotein cholesterol level decreased with initiation of evolocumab (69%)”

    Humansin multidisciplinary cardiometabolic clinic patients

    Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol

    Internal medicine journal

  5. Evolocumab is linked with lower LDL-C in humans (combined with atorvastatin compared to atorvastatin alone) (P < 0.001).

    “the intensive treatment group showed a more pronounced reduction (P < 0.001).”

    Humanscombined with atorvastatin compared to atorvastatin alone6 monthsn = 34

    Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study

    PeerJ

More on LDL-C

Mortality

downin humans4HR 0.71–0.8

4 studies
  1. Evolocumab decreases mortality in humans (Reduced eGFR; without prior MI or stroke; compared with placebo) (12.0% versus 16.7%; absolute risk reduction 4.7%; HR 0.71, 95% CI 0.56-0.90).

    “12.0% vs. 16.7% (ARR 4.7%) in the evolocumab versus placebo arms (HR 0.71; 95% CI 0.56-0.90)”

    Human trialReduced eGFR; without prior MI or stroke; compared with placebo5 years55% femalesn = 2,140

    Evolocumab cut combined heart and stroke risk in kidney impairment

    Journal of the American College of Cardiology

  2. Evolocumab decreases mortality in humans (patients without previous myocardial infarction or stroke) (HR 0.80, 95% CI 0.70-0.91; P=0.0005).

    “All-cause mortality rates were 20% lower with evolocumab compared with placebo”

    Human trialpatients without previous myocardial infarction or stroke

    Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial

    Circulation

  3. Evolocumab decreases mortality in high-risk diabetes and non-high-risk diabetes subgroups (nominally lower; no value given).

    “Nominally lower mortality with evo was observed in both subgroups.”

    Human trialin high-risk diabetes and non-high-risk diabetes subgroups140 mg every 2 weeks4.6 years median follow-upn = 6,002

    Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial

    ADA Scientific Sessions 2026 abstract

  4. Evolocumab decreases mortality in humans (network meta-analysis of all-cause mortality).

    “evolocumab was most effective in lowering all-cause mortality”

    Reviewnetwork meta-analysis of all-cause mortalityn = 43,625

    Safety and efficacy of low-density lipoprotein-lowering drugs in the elderly: a network meta-analysis of randomized controlled trials

    Journal of geriatric cardiology : JGC

Lipoprotein

downin humans2

2 studies
  1. Evolocumab is linked with lower lipoprotein in humans (add-on to statin in CHIP-NSTEACS patients).

    “Evolocumab also significantly reduced lipoprotein(a)”

    Humansadd-on to statin in CHIP-NSTEACS patients

    Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study

    Frontiers in cardiovascular medicine

  2. Evolocumab decreases lipoprotein in humans (versus placebo) (−36.0 percentage points versus placebo; 95% CI −42.0 to −30.0).

    “evolocumab (−36.0; 95% CI, −42.0 to −30.0)”

    Reviewversus placebo

    Comparative Efficacy and Safety of PCSK9-Targeting Therapies for Lipoprotein(a) Reduction: A Systematic Review and Network Meta-Analysis

    Frontiers in cardiovascular medicine

More on Lipoprotein

Low-density lipoprotein cholesterol

downin humans2

2 studies
  1. Evolocumab decreases low-density lipoprotein cholesterol in humans (lipid substudy) (median 52 mg/dL vs 111 mg/dL at 48 weeks).

    “the median LDL-C level at 48 weeks was 52 mg/dL in the evolocumab group vs 111 mg/dL in the placebo group (P < .001)”

    Human triallipid substudy140 mg every 2 weeks48 weeks

    Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial

    JAMA

  2. Evolocumab is linked with lower low-density lipoprotein cholesterol in humans (combined with atorvastatin, versus atorvastatin monotherapy) (1.71 ± 0.49 vs 1.08 ± 0.32 mmol/L, P < 0.001).

    “low-density lipoprotein cholesterol (1.71 ± 0.49 mmol/L vs. 1.08 ± 0.32 mmol/L, P < 0.001)”

    Humanscombined with atorvastatin, versus atorvastatin monotherapythree monthsn = 76

    Effects of evolocumab combined with statin therapy on blood lipids, inflammatory factors, and endothelial function in patients with coronary heart disease

    BMC cardiovascular disorders

More on Low-density lipoprotein cholesterol

Body weight

no changein humans1

1 study
  1. Evolocumab showed no clear effect on body weight in humans (190±34 to 191±34 lb; p=0.66).

    “Weight (190±34 to 191±34 lb, p=0.66) and BMI (27.5±4.4 to 27.7±4.5 kg/m 2 , p=0.47) were unchanged.”

    Human trialSingle-arm before-and-after comparison in patients with extensive noncalcified plaque burden18 monthsn = 35

    Serial Assessment of AI-Based Body Composition Change After 18 Months of Evolocumab Treatment: An EVOLVE Subanalysis

    AHA Scientific Sessions 2026 abstract

Epicardial adipose tissue volume

downin humans1

1 study
  1. Evolocumab decreases epicardial adipose tissue volume in humans (118.1±42.4 to 104.7±40.8 mL).

    “EAT volume decreased from 118.1±42.4 to 104.7±40.8 mL (p=0.007)”

    Human trialSingle-arm before-and-after comparison in patients with extensive noncalcified plaque burdenepicardial adipose tissue18 monthsn = 35

    Serial Assessment of AI-Based Body Composition Change After 18 Months of Evolocumab Treatment: An EVOLVE Subanalysis

    AHA Scientific Sessions 2026 abstract

Skeletal muscle volume

upin humans1

1 study
  1. Evolocumab increases skeletal muscle volume in humans (2165±535 to 2435±719 mL).

    “SM volume increased from 2165±535 to 2435±719 mL (p=0.002).”

    Human trialSingle-arm before-and-after comparison in patients with extensive noncalcified plaque burdenskeletal muscle18 monthsn = 35

    Serial Assessment of AI-Based Body Composition Change After 18 Months of Evolocumab Treatment: An EVOLVE Subanalysis

    AHA Scientific Sessions 2026 abstract

3-point major adverse cardiovascular events

downin humans1HR 0.61

1 study
  1. Evolocumab decreases 3-point major adverse cardiovascular events in humans (Reduced eGFR; without prior MI or stroke; compared with placebo) (39% reduction; HR 0.61, 95% CI 0.46-0.81; 5-year absolute risk reduction 4.0%).

    “After 4.6 years median follow-up, evolocumab decreased 3-P MACE rates by 39% (HR 0.61; 95% CI 0.46-0.81, P=0.0007)”

    Human trialReduced eGFR; without prior MI or stroke; compared with placebo4.6 years median follow-up55% femalesn = 2,140

    Evolocumab cut combined heart and stroke risk in kidney impairment

    Journal of the American College of Cardiology

Total 4-P MACE

downin humans1

1 study
  1. Evolocumab decreases total 4-P MACE in humans (20% fewer total events (IRR 0.80, 95% CI 0.71-0.90)).

    “and total events by 20% (IRR 0.80, 95% CI 0.71-0.90; p<0.001)”

    Human trial4-P MACE includes ischemia-driven arterial revascularization; first and subsequent events analyzed togethermedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    ESC Congress 2026 abstract

More on Total 4-P MACE

First 3-P MACE

downin humans1HR 0.75

1 study
  1. Evolocumab decreases first 3-P MACE in humans (first events) (25% lower risk of first event (HR 0.75)).

    “reduced the risk of first 3-P MACE by 25% (HR 0.75, 95% CI 0.65-0.86)”

    Human trialfirst eventsmedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    ESC Congress 2026 abstract

More on First 3-P MACE

Recurrent 3-P MACE

downin humans1

1 study
  1. Evolocumab decreases recurrent 3-P MACE in humans (subsequent events after a first event) (37% fewer recurrent events (IRR 0.63, 95% CI 0.42-0.94)).

    “recurrent events by 37% (incidence-rate ratio [IRR] 0.63, 95% CI 0.42-0.94)”

    Human trialsubsequent events after a first eventmedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    ESC Congress 2026 abstract

More on Recurrent 3-P MACE

Total 3-P MACE

downin humans1

1 study
  1. Evolocumab decreases total 3-P MACE in humans (first and subsequent events analyzed together with negative binomial regression) (27% fewer total events (IRR 0.73, 95% CI 0.63-0.86)).

    “total events by 27% (IRR 0.73, 95% CI 0.63-0.86; p<0.001)”

    Human trialfirst and subsequent events analyzed together with negative binomial regressionmedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    ESC Congress 2026 abstract

More on Total 3-P MACE

Angiography-derived microvascular resistance

no changein humans1

1 study
  1. Evolocumab showed no clear effect on angiography-derived microvascular resistance in humans (Stable coronary artery disease; evolocumab added to high-intensity statin therapy) (23.2 ± 5.3 vs. 23.8 ± 4.9 mmHg·s/dm; p=0.28).

    “AMR did not change (23.2 ± 5.3 vs. 23.8 ± 4.9 mmHg·s/dm; p=0.28).”

    Human trialStable coronary artery disease; evolocumab added to high-intensity statin therapycoronary artery26 weeks

    Serial ai based comprehensive coronary physiological assessment before and after intensive lipid lowering therapy: YELLOW III substudy

    ESC Congress 2026 abstract

More on Angiography-derived microvascular resistance

Radial wall strain

downin humans1

1 study
  1. Evolocumab decreases radial wall strain in humans (Stable coronary artery disease; evolocumab added to high-intensity statin therapy) (16.9 ± 4.2% vs. 14.9 ± 3.5%).

    “Intensive lipid lowering with Evolocumab improves epicardial coronary physiology and reduces RWS without affecting microvascular resistance.”

    Human trialStable coronary artery disease; evolocumab added to high-intensity statin therapycoronary artery26 weeks

    Serial ai based comprehensive coronary physiological assessment before and after intensive lipid lowering therapy: YELLOW III substudy

    ESC Congress 2026 abstract

More on Radial wall strain

All 43

What is evolocumab linked with?

20

Studies link evolocumab with 20 measures, most often major adverse cardiovascular events (5 studies), mortality (3) and stroke (3).

Major adverse cardiovascular events

downin humans5HR 0.42–0.75

5 studies
  1. Evolocumab is linked with a lower risk of major adverse cardiovascular events in non-revascularized CHIP-NSTEACS patients (HR = 0.42, 95% CI: 0.25-0.71).

    “early evolocumab as an independent protective factor against 3-month MACE (HR = 0.42, 95% CI: 0.25-0.71, P = 0.001)”

    Humansin non-revascularized CHIP-NSTEACS patients3 months

    Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study

    Frontiers in cardiovascular medicine

  2. Evolocumab is linked with a lower risk of major adverse cardiovascular events in humans (initiated in hospital on top of high-intensity statin therapy) (HR 0.48, 95% CI 0.22-0.94; 10.0% vs 24.4%).

    “with lower risk in EVOLOCUMAB (HR 0.48, 95% CI 0.22-0.94; p = 0.035)”

    Humansinitiated in hospital on top of high-intensity statin therapy140 mg every two weeks24 monthsn = 71

    Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting

    Frontiers in cardiovascular medicine

  3. Evolocumab lowers the risk of major adverse cardiovascular events in humans (3-point MACE: HR 0.75 (95% CI 0.65 to 0.86); 4-point MACE: HR 0.81 (95% CI 0.73 to 0.89)).

    “Evolocumab lowered 3-point MACE (coronary heart disease death, MI, or ischemic stroke) by 25% (hazard ratio 0.75; 95% CI 0.65 to 0.86)”

    ReviewAtherosclerosis or high-risk diabetes without prior myocardial infarction or stroke; compared with placebomedian follow-up 4.6 yearsn = 12,257

    PCSK9 Inhibitors for the Primary Prevention of Major Cardiovascular Events in High-Risk Adults Without Prior Myocardial Infarction or Stroke: A Systematic Review and Meta-Analysis

    AHA Scientific Sessions 2026 abstract

  4. Evolocumab lowers the risk of major adverse cardiovascular events in humans (OR 0.75, 95% CI 0.64–0.88).

    “evolocumab demonstrated the greatest reduction in MACE, CV mortality, and stroke incidence”

    ReviewHigh cardiovascular risk; eligible studies had fewer than 10% of patients with a documented history of stroken = 78,146

    Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials

    ESC Congress 2026 abstract

  5. Evolocumab lowers the risk of major adverse cardiovascular events in humans (hypercholesterolemia; versus control) (OR 0.85, 95% CrI 0.79–0.92).

    “For MACE, evolocumab (OR 0.85, 95% CrI 0.79–0.92) and alirocumab (0.87, 0.80–0.95) significantly reduced cardiovascular events”

    Reviewhypercholesterolemia; versus control

    Comparative LDL-C Reduction and Cardiovascular Outcomes With PCSK9-Pathway Therapies: A Systemic Review and Network Meta-Analysis

    ESC Congress 2026 abstract

Mortality

downin humans3RR 0.53

3 studies
  1. Evolocumab lowers the risk of mortality in humans (CKD without prior MI or stroke; compared with placebo) (12.0% versus 16.7%; HR 0.71, 95% CI 0.56–0.90).

    “all-cause death in patients with CKD were 12.0% vs. 16.7% in the evolocumab vs. placebo arms (HR 0.71; 95% CI 0.56–0.90)”

    Human trialCKD without prior MI or stroke; compared with placebo5 years55% femalesn = 2,140

    Evolocumab reduced cardiovascular risk in kidney disease

    AHA Scientific Sessions 2026 abstract

  2. Evolocumab lowers the risk of mortality in humans (patients with diabetes and without known significant atherosclerosis; secondary endpoint) (HR 0.76 [95% CI, 0.61-0.95]).

    “There were 136 deaths (5-year Kaplan-Meier estimate, 7.8%) in the evolocumab group compared with 172 deaths”

    Human trialpatients with diabetes and without known significant atherosclerosis; secondary endpoint140 mg every 2 weeksmedian follow-up 4.8 yearsn = 3,655

    Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial

    JAMA

  3. Evolocumab is associated with mortality in humans (Analysis A: versus alirocumab; high-risk primary prevention) (1.4% vs 2.7%; RR 0.53, 95% CI 0.36-0.78).

    “evolocumab versus alirocumab was associated with lower mortality (1.4% vs 2.7%; RR 0.53, 95% CI 0.36-0.78)”

    HumansAnalysis A: versus alirocumab; high-risk primary prevention3 years

    Evolocumab linked to fewer deaths in high-risk adults

    AHA Scientific Sessions 2026 abstract

Stroke

downin humans3HR 0.76–0.77

3 studies
  1. Evolocumab lowers the risk of stroke in humans (HR 0.76, 95% CI 0.61-0.95).

    “Evolocumab reduced the relative rate of any stroke by 24% compared with placebo (5-Yr Kaplan-Meier, 2.6% vs 3.2%; HR 0.76, 95% CI 0.61-0.95; p=0.018)”

    Human trial4.6 years

    Evolocumab reduced first-stroke risk in high-risk patients

    AHA Scientific Sessions 2026 abstract

  2. Evolocumab lowers the risk of stroke in humans (achieved LDL-C <40 mg/dl in patients with prior ischemic stroke) (lowest IRs below 40 mg/dl).

    “When LDL-C was modeled categorically, the lowest IRs for the primary endpoint and for stroke were observed in patients whose achieved LDL-C was below 40 mg/dl”

    Human trialachieved LDL-C <40 mg/dl in patients with prior ischemic stroke

    Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke

    AHA Scientific Sessions 2025 abstract

  3. Evolocumab is associated with stroke in humans (Compared with a weighted external control arm) (HR 0.77, 95% CI 0.64–0.93).

    “For MI, stroke, and CV death, the HR (95% CI) was 0.63 (0.55, 0.72), 0.77 (0.64, 0.93), and 0.75 (0.63, 0.88), respectively.”

    HumansCompared with a weighted external control armMedian 6.6 years; maximum 8.1 years

    Long-Term Effectiveness of Evolocumab in Reducing the Risk for Major Adverse Cardiovascular Events: Comparing FOURIER OLE Data to External Control Using a Principled Approach

    AHA Scientific Sessions 2026 abstract

More on Stroke

3-P MACE

downin humans2HR 0.61–0.69

2 studies
  1. Evolocumab lowers the risk of 3-P MACE in humans (CKD without prior MI or stroke; compared with placebo) (39% reduction; HR 0.61, 95% CI 0.46–0.81; 5-year ARR 4.0%).

    “evolocumab decreased 3-P MACE rates by 39% (HR 0.61; 95% CI 0.46–0.81, P=0.0007)”

    Human trialCKD without prior MI or stroke; compared with placeboMedian follow-up of 4.6 years55% femalesn = 2,140

    Evolocumab reduced cardiovascular risk in kidney disease

    AHA Scientific Sessions 2026 abstract

  2. Evolocumab lowers the risk of 3-P MACE in humans (HR 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference 2.1% [95% CI, 0.4%-3.8%]).

    “A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients”

    Human trialpatients with diabetes and without known significant atherosclerosis; dual primary endpoint140 mg every 2 weeksmedian follow-up 4.8 yearsn = 3,655

    Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial

    JAMA

LDL cholesterol

downin humans1

1 study
  1. Evolocumab is associated with LDL cholesterol in humans (Japanese patients with heterozygous familial hypercholesterolemia) (−54.0% from baseline at 104 weeks).

    “At 104 weeks, mean LDL‐C changes from baseline were −54.0% in patients with HeFH and −48.9% in patients with HoFH.”

    HumansJapanese patients with heterozygous familial hypercholesterolemia104 weeks

    Real‐World Safety and Effectiveness of Evolocumab in Japanese Patients With Familial Hypercholesterolemia: Postmarketing Survey Analysis

    Journal of the American Heart Association

More on LDL cholesterol

MACE-plus

downin humans1RR 0.66

1 study
  1. Evolocumab is associated with MACE-plus in humans (Analysis A: versus alirocumab; high-risk primary prevention) (RR 0.66, 95% CI 0.50-0.87).

    “lower MACE-plus (RR 0.66, 0.50-0.87)”

    HumansAnalysis A: versus alirocumab; high-risk primary prevention3 years

    Evolocumab linked to fewer deaths in high-risk adults

    AHA Scientific Sessions 2026 abstract

Cardiovascular mortality

downin humans1HR 0.75

1 study
  1. Evolocumab is associated with cardiovascular mortality in humans (Compared with a weighted external control arm) (HR 0.75, 95% CI 0.63–0.88).

    “For MI, stroke, and CV death, the HR (95% CI) was 0.63 (0.55, 0.72), 0.77 (0.64, 0.93), and 0.75 (0.63, 0.88), respectively.”

    HumansCompared with a weighted external control armMedian 6.6 years; maximum 8.1 years

    Long-Term Effectiveness of Evolocumab in Reducing the Risk for Major Adverse Cardiovascular Events: Comparing FOURIER OLE Data to External Control Using a Principled Approach

    AHA Scientific Sessions 2026 abstract

Myocardial infarction

downin humans1HR 0.63

1 study
  1. Evolocumab is associated with myocardial infarction in humans (Compared with a weighted external control arm) (HR 0.63, 95% CI 0.55–0.72).

    “For MI, stroke, and CV death, the HR (95% CI) was 0.63 (0.55, 0.72), 0.77 (0.64, 0.93), and 0.75 (0.63, 0.88), respectively.”

    HumansCompared with a weighted external control armMedian 6.6 years; maximum 8.1 years

    Long-Term Effectiveness of Evolocumab in Reducing the Risk for Major Adverse Cardiovascular Events: Comparing FOURIER OLE Data to External Control Using a Principled Approach

    AHA Scientific Sessions 2026 abstract

More on Myocardial infarction

3-point major adverse cardiovascular events

downin humans1HR 0.71

1 study
  1. Evolocumab is associated with 3-point major adverse cardiovascular events in humans (Compared with a weighted external control arm) (29% lower risk; HR 0.71, 95% CI 0.65–0.79).

    “patients treated with evolocumab had a 29% lower risk of 3P MACE (HR: 0.71 [95% CI: 0.65, 0.79]) compared with the ECA”

    HumansCompared with a weighted external control armMedian 6.6 years; maximum 8.1 years

    Long-Term Effectiveness of Evolocumab in Reducing the Risk for Major Adverse Cardiovascular Events: Comparing FOURIER OLE Data to External Control Using a Principled Approach

    AHA Scientific Sessions 2026 abstract

More on 3-point major adverse cardiovascular events

First myocardial infarction

downin humans1HR 0.64

1 study
  1. Evolocumab lowers the risk of first myocardial infarction in humans (36% risk reduction; HR 0.64, 95% CI 0.52–0.79; 5-year Kaplan-Meier incidence 2.7% vs 4.1%).

    “Evolocumab significantly reduced the risk of any MI by 36% compared with placebo”

    Human trialQualifying atherosclerosis or high-risk diabetes, no prior myocardial infarction or stroke, and LDL-C ≥90 mg/dL; compared with placebo on background optimized lipid-lowering therapyMedian follow-up of 4.6 yearsn = 12,257

    Evolocumab reduced first heart attacks in high-risk patients

    ESC Congress 2026 abstract

More on First myocardial infarction

First 3-point major adverse cardiovascular events

downin humans1HR 0.75

1 study
  1. Evolocumab lowers the risk of first 3-point major adverse cardiovascular events in humans (high cardiovascular risk with no prior MI or stroke) (-25%, HR 0.75).

    “reduced the rate of first events by 25% (HR: 0.75; 95% CI: 0.65-0.86; P < 0.0001)”

    Human trialhigh cardiovascular risk with no prior MI or strokemedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    Journal of the American College of Cardiology

First 4-point major adverse cardiovascular events

downin humans1HR 0.81

1 study
  1. Evolocumab lowers the risk of first 4-point major adverse cardiovascular events in humans (high cardiovascular risk with no prior MI or stroke) (-19%, HR 0.81).

    “Evolocumab reduced the rate of first 4-P MACE by 19% (HR: 0.81; 95% CI: 0.73-0.89; P < 0.0001)”

    Human trialhigh cardiovascular risk with no prior MI or strokemedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    Journal of the American College of Cardiology

3-point major adverse cardiovascular events

downin humans1

1 study
  1. Evolocumab lowers the risk of 3-point major adverse cardiovascular events in humans (high cardiovascular risk with no prior MI or stroke) (-27%, IRR 0.73).

    “reduced total events by 27% (IRR: 0.73; 95% CI: 0.63-0.86; P = 0.0001)”

    Human trialhigh cardiovascular risk with no prior MI or strokemedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    Journal of the American College of Cardiology

4-point major adverse cardiovascular events

downin humans1

1 study
  1. Evolocumab lowers the risk of 4-point major adverse cardiovascular events in humans (high cardiovascular risk with no prior MI or stroke) (-20%, IRR 0.80).

    “reduced total events by 20% (IRR: 0.80; 95% CI: 0.71-0.90; P = 0.0002)”

    Human trialhigh cardiovascular risk with no prior MI or strokemedian of 4.6 yearsn = 12,257

    Evolocumab reduced total cardiovascular events in high-risk patients

    Journal of the American College of Cardiology

Major adverse vascular events

downin humans1OR 7

1 study
  1. Evolocumab lowers the risk of major adverse vascular events in humans (2.4% vs 14.6%, OR 7 for absence of evolocumab).

    “At 1 year, MAVE were significantly more frequent with LLT (14.6% versus 2.4%, p=0.005), and the absence of evolocumab was the only predictor (OR 7, p=0.014).”

    Human trialon top of lipid-lowering therapy in patients with carotid stenosis >=50% and LDL-C >=100 mg/dL1 yearn = 170

    CARotid plaqUe StabilizatiOn and regression with evolocumab: the CARUSO Study

    medRxivPreprint

All 20

Has evolocumab been tested in people?

11 of 93 about aging

Yes: 22 trials and 29 observational studies in people have been published, and 89 trials are registered.

Approved

  • EMA Repatha

    Jul 17, 2015Dyslipidemias, Hypercholesterolemia, Atherosclerotic Cardiovascular Disease

  • FDA Repatha

    Aug 27, 2015Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia

Repurposing

40 of 43

Every condition in trials

  • Hyperlipidemias

    Phase 4Results posted19 trials

  • Hypercholesterolemia, Autosomal Dominant, 3

    Phase 4Recruiting8 trials

  • Hyperlipoproteinemia type II

    Phase 4Completed6 trials

  • Stable coronary disease

    Phase 4Recruiting1 trial

  • Psychological Inhibition

    Phase 3Results posted2 trials

  • Pharmacodynamic

    Phase 1Results posted1 trial

All 8

Stopped

  • NCT03080935TerminatedDyslipidemias

    Amgen business decision to close study early

  • NCT05613426TerminatedST-elevation myocardial infarction

    Slow patient enrollment and lack of financial support

  • NCT03337698TerminatedNon-small cell lung cancer

    Study was closed early as the sponsor decided not to continue development of certain treatment combinations.

Who is developing evolocumab?

1 company: Amgen.

Companies
  • AmgenPhase 4cardiovascular disease, myocardial infarction

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Evolocumab lowers mortality in people without prior myocardial infarction or stroke in a human trial; independent labs report lower LDL cholesterol and fewer cardiovascular events. An extension trial shows no clear executive-function effect. Amgen sponsors most trials across uses; 11 registered trials concern aging, and eight trials ended over a year ago without posted results.

  2. Summary rewritten as its findings changed.

    As it read before

    Evolocumab lowers mortality in patients without prior myocardial infarction or stroke in a human trial; independent labs reproduce reductions in cardiovascular events and LDL cholesterol. An extension shows no clear executive-function effect. Amgen funds papers and sponsors most trials; five registered trials concern aging, and eight trials ended over a year ago without posted results or a citing paper.

  3. Summary rewritten as its findings changed.

    As it read before

    Evolocumab reduces cardiovascular events and mortality in human trials involving patients with atherosclerosis or high-risk diabetes without prior myocardial infarction or stroke. Independent labs reproduce LDL reductions and cardiovascular-event associations; a short trial on high-intensity statins shows no clear plaque-volume effect. Five trials concern aging; across all uses, eight ended over a year ago without posted results; developer Amgen sponsors most.

  4. Summary rewritten as its findings changed.

    As it read before

    A human trial shows evolocumab lowers cardiovascular event risk in high-risk adults without previous myocardial infarction or stroke; a trial also reports lower overall and cardiovascular mortality. A human study reports lower LDL cholesterol when added to statins in CHIP-NSTEACS patients.

  5. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 4Feb 2026: 5Mar 2026: 11Apr 2026: 0May 2026: 1Jun 2026: 1Jul 2026: 2Aug 2026: 5Sep 2026: 2Oct 2026: 12Nov 2026: 3073 papers in 12 months
Journal of the American College of Cardiology

Evolocumab cut combined heart and stroke risk in kidney impairment

Evolocumab reduced the relative risk of coronary heart disease death, heart attack or stroke by 39% versus placebo in people with reduced kidney function.Evolocumab reduced the relative risk of coronary heart disease death, heart attack or stroke by 39% versus placebo in people with reduced kidney function.

Randomized trial · 2,140 peopleEvolocumab
AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Cohort studyEvolocumab

See all 86 papers on evolocumab